Sung Ho Moon1, Kwan Ho Cho2, Eun Ji Chung3, Chang Geol Lee4, Kyu Chan Lee5, Gyu-Young Chai6, Ki Mun Kang6, Jong Young Lee7, Woong-Ki Chung8, Woo Yoon Park9, Jin Hee Kim10. 1. Research Institute and Hospital, National Cancer Center, Republic of Korea. 2. Research Institute and Hospital, National Cancer Center, Republic of Korea. Electronic address: kwancho@ncc.re.kr. 3. National Health Insurance Service, Ilsan Hospital, Republic of Korea. 4. Yonsei University College of Medicine, Republic of Korea. 5. Gachon University Gil Medical Center, Republic of Korea. 6. Gyeongsang National University Hospital, Republic of Korea. 7. Wonju Severance Christian Hospital, Republic of Korea. 8. Chonnam National University College of Medicine, Republic of Korea. 9. Chungbuk National University Hospital, Republic of Korea. 10. Keimyung University Dongsan Medical Center, Republic of Korea.
Abstract
BACKGROUND AND PURPOSE: To prospectively investigate the effect of radiotherapy fraction size on clinical outcomes in early glottic carcinoma METHODS AND MATERIALS: Patients with T1-2 glottic carcinoma were eligible for the protocol. Although 282 patients were required, the study was closed prematurely due to poor accrual with only 156 patients. Of these, 82 patients were allocated to conventional fractionation (CONV) arm (66 Gy/33 fractions for T1 and 70 Gy/35 fractions for T2), with 74 patients to hypofractionation (HYPO) arm (63 Gy/28 fractions for T1 and 67.5 Gy/30 fractions for T2). The primary objective was local progression-free survival (LPFS). RESULTS: With a median follow-up of 67 months (range, 2-122 months), the 5-year LPFS was 77.8% for CONV arm and 88.5% for HYPO arm (HR 1.55, p=0.213). No significant difference was observed in the toxicity profile between the two arms. In a subgroup exploratory analysis for T1a disease, the 5-year LPFS trended positively in HYPO arm (76.7% vs. 93.0%, HR 3.65, p=0.056). CONCLUSIONS: Given that HYPO is at least not inferior to CONV with a similar toxicity profile, the hypofractionation scheme used in this study can be offered to patients with T1-2 glottic carcinoma with potential advantages in terms of local control and a shortened overall treatment time.
RCT Entities:
BACKGROUND AND PURPOSE: To prospectively investigate the effect of radiotherapy fraction size on clinical outcomes in early glottic carcinoma METHODS AND MATERIALS: Patients with T1-2glottic carcinoma were eligible for the protocol. Although 282 patients were required, the study was closed prematurely due to poor accrual with only 156 patients. Of these, 82 patients were allocated to conventional fractionation (CONV) arm (66 Gy/33 fractions for T1 and 70 Gy/35 fractions for T2), with 74 patients to hypofractionation (HYPO) arm (63 Gy/28 fractions for T1 and 67.5 Gy/30 fractions for T2). The primary objective was local progression-free survival (LPFS). RESULTS: With a median follow-up of 67 months (range, 2-122 months), the 5-year LPFS was 77.8% for CONV arm and 88.5% for HYPO arm (HR 1.55, p=0.213). No significant difference was observed in the toxicity profile between the two arms. In a subgroup exploratory analysis for T1a disease, the 5-year LPFS trended positively in HYPO arm (76.7% vs. 93.0%, HR 3.65, p=0.056). CONCLUSIONS: Given that HYPO is at least not inferior to CONV with a similar toxicity profile, the hypofractionation scheme used in this study can be offered to patients with T1-2glottic carcinoma with potential advantages in terms of local control and a shortened overall treatment time.
Authors: Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin Journal: Strahlenther Onkol Date: 2017-05-04 Impact factor: 3.621
Authors: Zbigniew Szutkowski; Andrzej Kawecki; Andrzej Jarząbski; Zofia Laskus; Romuald Krajewski; Wojciech Michalski; Paweł Kukołowicz Journal: Rep Pract Oncol Radiother Date: 2016-09-20
Authors: B G Salas-Salas; D J Domínguez-Nuez; R Cabrera; L Ferrera-Alayón; M Lloret; P C Lara Journal: Clin Transl Oncol Date: 2019-06-01 Impact factor: 3.405
Authors: William A Stokes; Diana Abbott; Andy Phan; David Raben; Ryan M Lanning; Sana D Karam Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-06 Impact factor: 7.038
Authors: Andy Trotti; Qiang Zhang; Søren M Bentzen; Bahman Emami; M Elizabeth Hammond; Christopher U Jones; William H Morrison; Stephen M Sagar; John A Ridge; Karen K Fu; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038
Authors: Karine A Al Feghali; Bassem Y Youssef; Abdallah S R Mohamed; Lara Hilal; Blaine D Smith; Ibrahim Abu-Gheida; Georges Farha; G Brandon Gunn; Jack Phan; Jan Lewin; Apurva Thekdi; William H Morrison; Adam S Garden; Clifton David Fuller; David I Rosenthal Journal: Head Neck Date: 2020-06-02 Impact factor: 3.147